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Introduction
There has been considerable interest in recent 
years in the potential of cladribine, an adenosine 
analogue synthetic prodrug,1 for the treatment of 
patients with multiple sclerosis (MS). In the 
CLARITY (CLAdRIbine tablets Treating multi-
ple sclerosis orally) [ClinicalTrials.gov identifier: 
NCT00213135] study, patients with relapsing–
remitting multiple sclerosis (RRMS) were rand-
omized to receive either placebo or a cumulative 
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Abstract
Background: The CLARITY and CLARITY Extension studies demonstrated that treatment 
of relapsing–remitting multiple sclerosis (RRMS) with cladribine tablets (CT) results in 
significant clinical improvements, compared with placebo. This paper presents the key 
magnetic resonance imaging (MRI) findings from the CLARITY Extension study.
Methods: Patients who received a cumulative dose of either CT 3.5 or 5.25 mg/kg in CLARITY 
were rerandomized to either placebo or CT 3.5 mg/kg in CLARITY Extension. Patients from the 
arm that received placebo in CLARITY were assigned to CT 3.5 mg/kg. MRI assessments were 
carried out when patients entered CLARITY Extension and after Weeks 24, 48, 72 and 96, and 
in a supplemental follow-up period.
Results: At CLARITY Extension baseline, patients who received placebo during CLARITY 
had more T1 gadolinium-enhanced (Gd+) lesions than patients who received CT during 
CLARITY. These patients, who were then exposed to cladribine 3.5 mg/kg during the extension, 
experienced a 90.4% relative reduction (median difference −0.33, 97.5% confidence interval 
−0.33–0.00; p < 0.001) in T1 Gd+ lesions at the end of the extension compared with the end 
of CLARITY. Overall, the majority of patients in each treatment group remained free from T1 
Gd+ lesions throughout CLARITY Extension. However, a small proportion of patients who 
were treated with cladribine in CLARITY and received placebo in CLARITY Extension showed 
evidence of increased MRI activity, and this was associated with a prolonged treatment gap 
between CLARITY and CLARITY Extension.
Conclusion: A 2-year treatment with CT 3.5 mg/kg has a durable effect on MRI outcomes in 
the majority of patients, an effect that was sustained in patients who were not retreated in the 
subsequent 2 years after initial treatment.
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dose of cladribine tablets (CT) of 3.5 or 5.25 mg/
kg bodyweight over 2 years.2 Both CT doses 
resulted in significant clinical improvements in 
relapse rate, disability progression, as well as in 
magnetic resonance imaging (MRI) outcomes, 
compared with placebo.2
The significant benefits observed with respect to 
MRI activity outcomes for CT 3.5 and 5.25 mg/
kg versus placebo in CLARITY were analyzed in 
greater detail:3 (1) the proportion of patients with 
no active T1 gadolinium-enhancing (Gd+), 
active T2 or combined unique (CU) lesions was 
significantly greater for both doses of CT than 
placebo; (2) the lesion-free proportion was sig-
nificantly greater with CT than placebo regard-
less of whether patients had experienced ⩽1, 2 or 
⩾3 relapses in the 12 months prior to study 
entry.3
Following completion of CLARITY, patients 
were given the option to enrol in the CLARITY 
Extension study (ClinicalTrials.gov identifier: 
NCT00641537) to investigate the safety, tolera-
bility and efficacy of two additional years of treat-
ment with CT or placebo beyond the initial 2-year 
CLARITY regimen.4 There was a variable treat-
ment gap (median duration: 40.3 weeks) between 
the end of CLARITY and the start of CLARITY 
Extension.4 This provided a prolonged follow-up 
period for the assessment of efficacy, safety and 
tolerability of treatment with CT and is a factor 
for consideration in the analysis and interpreta-
tion of outcomes.
MRI measurements are an important tool in MS 
studies and in routine monitoring, providing 
important insights into disease activity, predicting 
clinical progression and the efficacy of treat-
ments.5,6 Brain volume loss has been associated 
with T1 hypointense lesion volume, T1 Gd+ 
lesion count and new/enlarged T2 lesion count.6 
In this paper, we present the MRI findings from 
the CLARITY Extension study.
Methods
The design and methodology of CLARITY 
Extension is described elsewhere.4 The CLARITY 
Extension protocol complied with the Declaration 
of Helsinki and standards of Good Clinical 
Practice according to the International Conference 
on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. 
The protocol was approved by the relevant ethics 
committees and institutional review boards of par-
ticipating centres. Written, informed consent was 
obtained from all participants. After completing 
treatment in CLARITY, eligible patients had the 
option of entering the 96-week (2-year) Extension, 
with the blind maintained. Randomization and 
double blinding were performed in accordance 
with the procedures used in CLARITY.2
Patients treated with placebo in CLARITY were 
allocated to CT 3.5 mg/kg, and patients who 
received active treatment in CLARITY were 
rerandomized to receive CT 3.5 mg/kg or pla-
cebo. There were five treatment groups in 
CLARITY Extension (Figure 1):
(1) CP 3.5 mg/kg (CT 3.5 mg/kg in CLARITY/
placebo in CLARITY Extension)
(2) CP 5.25 mg/kg (CT 5.25 mg/kg in 
CLARITY/placebo in CLARITY 
Extension)
(3) CC 7.0 mg/kg (CT 3.5 mg/kg in CLARITY/
CT 3.5 mg/kg in CLARITY Extension)
(4) CC 8.75 mg/kg (CT 5.25 mg/kg in 
CLARITY/CT 3.5 mg/kg CLARITY 
Extension)
(5) PC 3.5 mg/kg (placebo in CLARITY/CT 
3.5 mg/kg in CLARITY Extension).
Since the CLARITY Extension study was not 
prespecified, an administrative gap period 
occurred between the end of CLARITY and the 
start of the CLARITY Extension (Figure 1). 
Patients who had already completed their last 
visit and had exited CLARITY were recontacted 
to be transitioned into the CLARITY Extension. 
Patients who had required and started treatment 
with interferon-β or glatiramer acetate during the 
gap period had to discontinue their disease-mod-
ifying drug (DMD) at least 3 months before the 
first day of the Extension. The number of patients 
(n = 6) who received a DMD between CLARITY 
and CLARITY Extension was low (treated with 
placebo during CLARITY, n = 4; treated with 
CT 3.5 mg/kg during CLARITY, n = 2). After 
CLARITY Extension, patients were eligible to 
enter a 6-month supplemental follow up during 
which they could receive DMD treatment if 
required, but not CT. MRI data from the sup-
plemental follow up were included in these 
analyses.
MRI scans were performed using a standardized 
operating protocol (described in a dedicated 
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users’ manual) to ensure consistency and quality. 
Operators were blinded to trial treatment and 
patients were scanned using the same machines 
throughout the trial. A central independent neu-
roradiology center (WorldCare Clinical LLC, 
Boston, MA, USA), also blinded to treatment, 
was used to assess MRI scans.
Assessments of MRI activity were carried out when 
patients entered CLARITY Extension and after 
Weeks 24, 48, 72 and 96 of double-blind treat-
ment, and at the start and end of a 6-month sup-
plemental follow-up period (unless the final 
double-blind period assessment was within 4 weeks 
of the start of the supplemental follow up). For 
missing baseline measurements, data could be used 
from a measurement if it occurred within 7 days of 
the first dose date or 4 weeks prior to study day 1. 
The prespecified endpoints assessed included:
(1) Number of T1 Gd+ lesions.
(2) Number of active T2 lesions (new or 
enlarged lesions).
(3) Total T2 lesion volume.
(4) Proportion of patients with no T1 Gd+ 
lesions.
(5) Proportion of patients with no active T2 
lesions.
The design of CLARITY Extension did not per-
mit the treatment versus placebo comparisons used 
in CLARITY, and the prespecified analyses used a 
similar approach to assess clinical and neurological 
outcomes.4 Efficacy objectives were classified as 
exploratory; determinations of statistical signifi-
cance should be regarded as nominal; a p value ⩽ 
0.025 was considered nominally significant. 
Comparisons were made between patients treated 
with CT in CLARITY and placebo in CLARITY 
Extension versus patients who received cladribine 
in both CLARITY and CLARITY Extension:
(1) CP 3.5 mg/kg was compared with CC 7.0 
mg/kg, and CP 5.25 mg/kg was compared 
with CC 8.75 mg/kg
Figure 1. CLARITY and CLARITY Extension study plan.
Assessments of MRI activity were carried out when patients entered CLARITY Extension and after Weeks 24, 48, 72 and 96 of 
double-blind treatment, and at the start and end of a 6-month supplemental follow-up period (unless the final double-blind 
period assessment was within 4 weeks of the start of the supplemental follow up).
†patients who received placebo in CLARITY were assigned to treatment with cladribine 3.5 mg/kg in CLARITY Extension.
‡patients who received cladribine 3.5 mg/kg or 5.25 mg/kg in CLARITY were rerandomized to receive placebo or cladribine 
3.5 mg/kg in CLARITY Extension.
PC 3.5 mg/kg, placebo in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CP 3.5 mg/kg, cladribine 3.5 mg/kg in 
CLARITY/placebo in CLARITY Extension; CC 7.0 mg/kg, cladribine 3.5 mg/kg in CLARITY/cladribine 3.5 mg/kg in CLARITY 
Extension; CC 8.75 mg/kg, cladribine 5.25 mg/kg in CLARITY/cladribine 3.5 mg/kg CLARITY Extension; CP 5.25 mg/kg, 
cladribine 5.25 mg/kg in CLARITY/placebo in CLARITY Extension; SUPF, supplemental follow up; MRI, magnetic resonance 
imaging; RRMS, relapsing–remitting multiple sclerosis.
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(2) Also, CP 3.5 mg/kg was compared with 
PC 3.5 mg/kg.
A pooled comparison of all patients in the two 
CC groups against a pool of all patients in the CP 
groups was also conducted. A comparison of a 
pool of all patients in the two CC groups against 
a pool of all patients in the CP groups was also 
conducted. Post hoc analyses included investiga-
tion of the relationship between mean T1 Gd+ 
lesion numbers and treatment gap duration.
Results
Patients and baseline data
Full demographic and clinical details of patients 
included in CLARITY and CLARITY Extension 
have been described.2,4 Details of patients’ MRI 
and neurological characteristics at entry into the 
CLARITY and CLARITY Extension studies are 
shown in Table 1. Four or more postbaseline 
MRI scans were taken for 703 patients (87.2%; 
Table 2).
When patients entered CLARITY, baseline char-
acteristics were broadly similar across groups, 
although there was some variation in MRI char-
acteristics. The observed mean number of T1 
Gd+ lesions, which was 0.99 across all patients at 
CLARITY baseline (Figure 2), was lowest in the 
PC 3.5 mg/kg group, which also had the smallest 
volume of T1 Gd+ lesions (Table 1). The 
observed volume of T2 lesions and the number 
and volume of T1 hypointense lesions were also 
smallest in the PC 3.5 mg/kg group. In contrast, 
when patients entered CLARITY Extension, the 
observed mean number of T1 Gd+ lesions was 
higher in the PC 3.5 mg/kg group than the other 
groups (0.77 versus 0.10–0.31), and mean T1 
Gd+ lesion volume was also greater in this group 
(132.30 mm3) than in the others (18.45–49.19 
mm3, Table 1).
Duration of gap between CLARITY and CLARITY 
Extension
The gap period was distributed evenly across 
treatment groups: the median duration was 40.3 
weeks and the maximum duration was between 
111.0 weeks and 118.0 weeks across the groups 
(range 0.1–118.0 weeks across all groups). 
Overall, 10.7% of patients experienced a gap 
duration of ⩽4 weeks; 44.8% experienced a gap 
>4 to ⩽43 weeks, and 44.5% had a gap >43 
weeks.
T1 gadolinium-enhanced lesions
At the end of the CLARITY study, the observed 
mean number of T1 Gd+ lesions was lowest in 
the CP 3.5 and 5.25 mg/kg groups (0.07 each), 
followed by the CC 8.75 and 7 mg/kg groups 
(0.08 and 0.11, respectively) and highest in the 
group that received placebo in CLARITY (0.71; 
all 244 patients had MRI data available at the end 
of CLARITY). At entry to CLARITY Extension, 
the observed mean number of T1 Gd+ lesions in 
the PC 3.5 mg/kg group was still high, but then 
decreased following treatment with CT 3.5 mg/
kg. In a longitudinal evaluation, which compared 
treatment groups at the end of CLARITY with 
the same groups of patients at the end of 
CLARITY Extension, a relative reduction of 
90.4% [median difference −0.33 97.5% confi-
dence interval (CI) −0.33–0.00; p < 0.001] was 
seen in the mean number of T1 Gd+ lesions in 
the PC 3.5 mg/kg group (0.07) versus the end of 
CLARITY (0.68; 8/244 patients did not have 
MRI data available both at the end of CLARITY 
and the end of CLARITY Extension).
Across all treatment groups, the mean number of 
T1 Gd+ lesions at the end of CLARITY 
Extension was below 0.30 (Table 3), with the 
highest values in the CP 3.5 and 5.25 mg/kg 
groups. Between-group testing showed that the 
mean number of T1 Gd+ lesions in CP 3.5 mg/
kg was significantly higher than CC 7.0 mg/kg 
(treatment difference 0.00, 97.5% CI 0.00–0.00; 
p < 0.001), but CP 5.25 mg/kg did not reach sig-
nificance compared with CC 8.75 mg/kg. The 
pooled group of CP 3.5 and CP 5.25 mg/kg 
patients also showed a significantly higher mean 
number of T1 Gd+ lesions compared with the 
pooled group of CC 7.0 and CC 8.75 mg/kg 
patients (treatment difference 0.00, 97.5% CI 
0.00–0.00; p < 0.001).
The cumulative mean number of T1 Gd+ lesions 
was higher in the CP 3.5 mg/kg group [1.33; 
standard deviation (SD) 4.13] than the CC 7.0 
mg/kg group [0.13 (SD 0.41); relative risk 0.10, 
97.5% CI 0.03–0.29; p < 0.001]. A similar pat-
tern was observed for the CP 5.25 and the CC 
8.75 mg/kg groups (data not shown). In the 
pooled group of CC 7.0 and CC 8.75 mg/kg 
patients, the cumulative mean number of lesions 
was lower [0.5 (SD 4.22)] than in the pooled 
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group of CP 3.5 and CP 5.25 mg/kg patients 
[1.24 (SD 4.11); relative risk 0.13, 97.5% CI 
0.06–0.27; p < 0.001].
Patients with no new T1 gadolinium-enhanced 
lesions
At the end of CLARITY Extension, the propor-
tion of patients with no new T1 Gd+ lesions 
was high across all groups and ranged from 
73.0% to 89.9% (Table 3). The CP 3.5 and CP 
5.25 mg/kg groups had the lowest proportions 
of patients without any T1 Gd+ lesions. 
Between-group testing showed that this pro-
portion was significantly lower in the CP 3.5 
mg/kg group than the CC 7.0 mg/kg group 
(73.0% and 88.9%, respectively; odds ratio 
3.05, 97.5% CI 1.39–6.68; p = 0.001), but not 
in the CP 5.25 group compared with the 8.75 
mg/kg group (80.2% and 89.9%). In the pooled 
group of CP 3.5 and CP 5.25 mg/kg patients, 
the proportion who remained free from T1 
Gd+ lesions (76.5%) was significantly smaller 
than in the pooled group of CC 7.0 and CC 
8.75 mg/kg patients (89.4%; odds ratio 2.60, 
97.5% CI 1.46–4.65; p < 0.001).
Table 1. Baseline magnetic resonance imaging and neurological assessments at entry into CLARITY and CLARITY Extension.
CP 3.5 mg/kg 
(n = 98)
CP 5.25 mg/kg 
(n = 92)
CC 7.0 mg/kg 
(n = 186)
CC 8.75 mg/kg 
(n = 186)
PC 3.5 mg/kg 
(n = 244)
All  
(n = 806)
CLARITY baseline
 T1 hypointense lesions
Mean (SD) 8.09 (9.80) 9.41 (10.34) 7.29 (8.18) 8.40 (9.26) 6.74 (8.02) 7.72 (8.88)
Lesion volume (103 
mm3), mean (SD)
3.99 (5.46) 4.97 (7.71) 3.59 (5.92) 4.28 (5.33) 2.81 (3.95) 3.73 (5.50)
 T1 Gd+ lesions
Mean (SD) 1.21 (2.59) 1.25 (2.80) 1.00 (3.32) 0.90 (2.09) 0.85 (2.38) 0.99 (2.64)
Lesion volume (mm3), 
mean (SD)
228.43 (540.05) 282.49 (861.99) 189.23 (614.75) 217.24 (520.40) 145.61 (404.31) 197.85 (564.87)
 T2 lesions
Lesion volume (103 
mm3), mean (SD)
18.35 (17.60) 18.32 (18.82) 14.34 (17.05) 16.93 (18.09) 13.49 (12.80) 15.62 (16.52)
CLARITY Extension baseline
 T1 hypointense lesions
Mean n (SD) 13.53 (13.39) 13.72 (15.84) 11.46 (12.66) 12.96 (14.66) 13.28 (14.35) 12.87 (14.11)
Lesion volume (103 
mm3), mean (SD)
2.39 (3.15) 3.50 (7.47) 1.95 (2.68) 2.37 (3.66) 2.31 (3.97) 2.39 (4.15)
 T1 Gd+ lesions
Mean n (SD) 0.27 (0.96) 0.10 (0.49) 0.31 (1.56) 0.31 (1.29) 0.77 (1.85) 0.42 (1.47)
Lesion volume (mm3), 
mean (SD)
18.45 (68.14) 19.78 (108.84) 43.46 (245.13) 49.19 (266.98) 132.30 (415.18) 65.93 (293.52)
 T2 lesions
Lesion volume (103 
mm3), mean (SD)
18.57 (19.05) 16.95 (18.17) 13.69 (14.39) 15.76 (14.55) 16.43 (13.81) 15.96 (15.40)
CP 3.5 mg/kg, cladribine 3.5 mg/kg in CLARITY/placebo in CLARITY Extension; CP 5.25 mg/kg, cladribine 5.25 mg/kg in CLARITY/placebo in 
CLARITY Extension; CC 7.0 mg/kg, cladribine 3.5 mg/kg in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg, cladribine 5.25 
mg/kg in CLARITY/cladribine 3.5 mg/kg CLARITY Extension; PC 3.5 mg/kg, placebo in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; Gd+, 
gadolinium enhanced; MRI, magnetic resonance imaging; SD, standard deviation. 
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New T1 hypointense lesions
During CLARITY Extension, mean numbers of 
new T1 hypointense lesions were low (0.58–0.73 
across groups), and no significant differences 
were observed in between-group comparisons.
Relationship between T1 gadolinium-enhanced 
lesions and gap duration
The higher observed mean T1 Gd+ counts in 
patients who received placebo in CLARITY 
Extension (CP 3.5 and CP 5.25 mg/kg) appeared 
to be associated with a small subgroup of 
patients, particularly in the CP 3.5 mg/kg group. 
This was analyzed by assessing the proportion 
of patients with a mean number of T1 Gd+ 
lesions ⩾ 1.0. In the CP 5.25 mg/kg group, this 
proportion was 6.7%, and in the CP 3.5 mg/kg 
group it was 11.6%. The relationship between 
treatment gap duration and mean T1 Gd+ 
lesion numbers was also assessed. Mean num-
bers of T1 Gd+ lesions were lowest in patients 
who experienced the shortest treatment gaps 
between CLARITY and CLARITY Extension, 
with a suggestion of increased MRI activity in 
some patients who experienced a prolonged 
period without active treatment. In the CP 3.5 
mg/kg group, the highest mean number of T1 
Gd+ lesions was seen in patients who experi-
enced the longest treatment gap (>43 weeks, n 
= 42). However, this was not significantly dif-
ferent to the other gap durations in the CP 3.5 
mg/kg group, and the mean number of T1 Gd+ 
lesions in this group remained <1 across all gap 
durations (Figure 2). Furthermore, this pattern 
was not observed in the CP 5.25 mg/kg group. 
With regard to the proportion of patients who 
remained free from T1 Gd+ lesions, in the CP 
3.5 mg/kg group, this percentage was highest 
when the gap between CLARITY and CLARITY 
Extension was shortest and vice versa (Figure 3). 
Again, this pattern was not seen in the other 
treatment groups.
T2 lesions
At the end of CLARITY Extension, mean num-
bers of active T2 lesions were numerically higher 
in groups treated with placebo in CLARITY 
Extension (CP 3.5 and CP 5.25 mg/kg; Table 3). 
These differences reached statistical significance 
when comparing the pooled group of CC 7.0 and 
CC 8.75 mg/kg patients [1.0 (SD 2.28)] versus 
the pooled group of CP 3.5 and 5.25 mg/kg 
patients [1.43 (SD 3.09); treatment difference 
0.00, 97.5% CI −0.17–0.00; p = 0.019]. The 
other comparisons did not reach significance 
(data not shown).
The proportion of patients with no active T2 
lesions was higher in patients treated with CT in 
CLARITY Extension (CC 7.0, CC 8.75 and PC 
3.5 mg/kg) than in those who received placebo 
during CLARITY Extension (CP 3.5 and CP 
5.25 mg/kg; Table 3). The proportion of patients 
with no active T2 lesions was significantly lower 
for the CP 5.25 mg/kg group than the CC 8.75 
mg/kg group comparison only (27.6 and 43.7%, 
respectively; odds ratio 2.03, 97.5% CI 1.07–
3.85; p = 0.013).
Table 2. Number of magnetic resonance imaging scans for T1 gadolinium-enhanced lesion count.
Number of MRI scans CP 3.5 mg/
kg (n = 98)
CP 5.25 mg/
kg (n = 92)
CC 7.0 mg/kg 
(n = 186)
CC 8.75 mg/
kg (n = 186)
PC 3.5 mg/kg 
(n = 244)
Total  
(n = 806)
Baseline scan only, n (%) 3 (3.1) 2 (2.2) 8 (4.3) 6 (3.2) 8 (3.3) 27 (3.3)
One postbaseline scan, n (%) 4 (4.1) 2 (2.2) 5 (2.7) 5 (2.7) 4 (1.6) 20 (2.5)
Two postbaseline scans, n (%) 2 (2.0) 6 (6.5) 4 (2.2) 8 (4.3) 9 (3.7) 29 (3.6)
Three postbaseline scans, n (%) 3 (3.1) 2 (2.2) 11 (5.9) 6 (3.2) 5 (2.0) 27 (3.3)
Four postbaseline scans, n (%) 16 (16.3) 15 (16.3) 28 (15.1) 28 (15.1) 40 (16.4) 127 (15.8)
Five postbaseline scans, n (%) 34 (34.7) 36 (39.1) 56 (30.1) 66 (35.5) 92 (37.7) 284 (35.2)
Six postbaseline scans, n (%) 26 (26.5) 29 (31.5) 74 (39.8) 67 (36.0) 86 (35.2) 292 (36.2)
CC 7.0 mg/kg, cladribine 3.5 mg/kg in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg, cladribine 5.25 mg/kg in CLARITY/
cladribine 3.5 mg/kg CLARITY Extension; CP 3.5 mg/kg, cladribine 3.5 mg/kg in CLARITY/placebo in CLARITY Extension; CP 5.25 mg/kg, cladribine 
5.25 mg/kg in CLARITY/placebo in CLARITY Extension; PC 3.5 mg/kg, placebo in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; Gd+, 
gadolinium enhanced; MRI, magnetic resonance imaging.
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Safety
Full safety findings have been previously pub-
lished.4 Rates of adverse events (AEs) were gener-
ally similar between groups, with most AEs 
classified as mild or moderate. There were 89 
(11.0%) treatment discontinuations due to AEs 
and 11 patients (1.4%) withdrew from the study 
due to AEs.4
Table 3. Mean number of T1 gadolinium-enhanced and active T2 lesions/patient/scan and proportion of 
patients with no T1 gadolinium-enhanced or active T2 lesions at the end of CLARITY Extension.
Characteristic CP 3.5 mg/
kg (n = 98)
CP 5.25 mg/
kg (n = 92)
CC 7.0 mg/kg 
(n = 186)
CC 8.75 mg/
kg (n = 186)
PC 3.5 mg/kg 
(n = 244)
n (missing) 95 (3) 90 (2) 178 (8) 180 (6) 236 (8)
Mean number of 
T1 Gd+ lesions/
patient/scan, n (SD)
0.28 (0.87) 0.29 (1.14) 0.03 (0.08) 0.17 (1.04) 0.07 (0.38)
Patients with no T1 
Gd+ lesions, n (%)
65 (73.0) 65 (80.2) 144 (88.9) 152 (89.9) 188 (85.1)
Mean number of 
active T2 lesions/
patient/scan, n (SD)
1.42 (3.64) 1.44 (2.40) 0.88 (1.63) 1.13 (2.78) 1.07 (1.84)
Patients with no 
active T2 lesions, 
n (%)
32 (34.4) 24 (27.6) 64 (37.6) 76 (43.7) 91 (40.1)
CC 7.0 mg/kg, cladribine 3.5 mg/kg in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg, cladribine 
5.25 mg/kg in CLARITY/cladribine 3.5 mg/kg CLARITY Extension; CP 3.5 mg/kg, cladribine 3.5 mg/kg in CLARITY/placebo 
in CLARITY Extension; CP 5.25 mg/kg, cladribine 5.25 mg/kg in CLARITY/placebo in CLARITY Extension; PC 3.5 mg/kg, 
placebo in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; Gd+, gadolinium enhanced; SD, standard deviation.
Figure 2. Mean number of T1 gadolinium-enhanced lesions in all patients at CLARITY baseline and in the 
cladribine tablet 3.5 mg/kg in CLARITY/placebo in CLARITY Extension and 5.25 mg/kg groups during CLARITY 
Extension, according to gap duration.
Error bars indicate standard deviation.
CP, cladribine tablet in CLARITY/placebo in CLARITY Extension; Gd+, gadolinium enhanced.
Therapeutic Advances in Neurological Disorders 00(0)
8 journals.sagepub.com/home/tan
Rates of lymphopenia were higher in patients 
treated with CT during CLARITY Extension 
(Grade ⩾ 3 lymphocyte counts: 40.9 and 53.2% 
of CC 7.0 and 8.75 mg/kg, respectively) com-
pared with placebo recipients (5.1 and 6.5% of 
CP 3.5 and 5.25 mg/kg, respectively). Of those 
patients in the CC 7.0 mg/kg group who experi-
enced Grade ⩾ 3 lymphocyte counts, >90% 
recovered to Grade 0–1 by study end.4 In the CP 
3.5 mg/kg group, five patients experienced Grade 
⩾ 3 lymphocyte counts and all recovered to 
Grade 0–1 by study end. Overall, 11 patients 
(1.4%) developed a malignancy or unspecified 
tumour. There were no reports of progressive 
multifocal leukoencephalopathy.4
Discussion
The clinical significance of changes in MRI activ-
ity in patients with MS has not been fully charac-
terized, although changes in MRI activity have 
previously been shown to correlate with relapse 
and disease activity.7,8 The total number and area 
of T1 Gd+ lesions can significantly predict the 
onset of clinical worsening and increasing 
Expanded Disability Status Scale (EDSS) score.8 
A pooled analysis of 23 randomized, double-blind, 
placebo-controlled trials involving 6591 patients 
with RRMS found a strong correlation between 
relapses and MRI activity, with >80% of the vari-
ance in the combined treatment effects being 
explained by the variance in MRI activity.7 MRI 
lesion activity has also been suggested to predict 
clinical activity and conversion to MS in patients 
with early MS.9–11 Reflecting this, the McDonald 
diagnostic criteria include MRI as part of the 
assessment, recognizing it as a sensitive surrogate 
of disease activity and clinical events.12–14
Given the context of the relationship between 
MRI activity and MS progression, and the fact 
that all patients had received cladribine by the 
end of CLARITY Extension, it is noteworthy that 
MRI activity was, overall, low during CLARITY 
Extension. The mean number of T1 Gd+ lesions 
was low across all treatment groups, and although 
the mean values were higher in the two CP groups 
relative to the two CC groups, the values in each 
of these groups were considerably below those 
observed at baseline in the CLARITY study. This 
highlights another important aspect of these find-
ings, that there was no evidence of rebound dis-
ease in the groups that received placebo during 
CLARITY Extension.
Figure 3. Proportion of patients with no T1 gadolinium-enhanced lesions in the cladribine tablet 3.5 mg/kg 
in CLARITY/placebo in CLARITY Extension and 5.25 mg/kg groups during CLARITY Extension according to gap 
duration.
Error bars indicate 95% confidence intervals.
CP, cladribine tablet in CLARITY/placebo in CLARITY Extension; Gd+, gadolinium enhanced.
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There were some increases in lesion volume and 
fewer patients remained free from new lesions in 
patients who switched from CT in CLARITY to 
placebo in CLARITY Extension, particularly the 
CP 3.5 mg/kg group, compared with patients who 
received CT in both studies. Compared with 
patients randomized to placebo in the CLARITY 
study, those treated with CT had a considerably 
lower mean number and smaller volume of T1 
Gd+ lesions at CLARITY Extension baseline 
(Table 1). Furthermore, patients who received 
placebo in CLARITY followed by CT 3.5 mg/kg 
in CLARITY Extension went on to experience a 
relative reduction in the mean number of T1 
Gd+ lesions of 90.4% (median difference −0.33, 
97.5% CI −0.33–0.00; p < 0.001) compared with 
the end of CLARITY. This observation provides 
further support for the findings of the original 
CLARITY study.2
Patients in both groups that were switched from 
CT in CLARITY to placebo in CLARITY 
Extension (CP 3.5 and 5.25 mg/kg) showed a 
relatively small increase in mean numbers of T1 
Gd+ or active T2 lesions at the end of the study 
compared with the groups that continued to 
receive treatment with CT (CC 7.0 and 8.75 mg/
kg). This increase in MRI activity was nominally 
significant for the CP 3.5 mg comparison, but not 
the 5.25 mg/kg group, possibly reflecting an effect 
of the dosage administered during CLARITY, 
although the study was not powered to compare 
treatment effects between groups in this way. 
Despite these minor increases, the mean numbers 
of T1 Gd+ lesions in the CP 3.5 and 5.25 mg/kg 
groups remained low, and below the values 
observed at CLARITY baseline. Furthermore, a 
high proportion of patients remained free from 
T1 Gd+ lesions in the CP 3.5 and 5.25 mg/kg 
groups during CLARITY Extension (CP 3.5 and 
5.25 mg/kg, 73.0 and 80.2%, respectively). This 
indicates that in the majority of patients, 2 years 
of treatment with CT in CLARITY resulted in a 
sustained absence of MRI activity. The uptick in 
the proportion of patients with an increased num-
ber of T1 Gd+ lesions in the CP 3.5 and 5.25 
mg/kg groups may have been seen in patients who 
experienced a prolonged treatment gap between 
CLARITY and CLARITY Extension. This sug-
gests that CT has a durable impact that prevents 
or slows MRI activity in patients with RRMS.
Patients with a longer treatment gap between 
CLARITY and CLARITY Extension were more 
likely to experience MRI activity than patients 
with a shorter treatment gap. Post hoc analyses 
indicated that patients in the CP 3.5 mg/kg group 
who had experienced prolonged treatment gaps 
between CLARITY and CLARITY Extension 
were more likely to experience T1 Gd+ lesions 
than patients who had experienced shorter gaps 
between CLARITY and CLARITY Extension. 
The patients who experienced prolonged treat-
ment gaps finished CLARITY Extension between 
5.5 years and 6.5 years after entering CLARITY. 
Therefore, patients receiving placebo in 
CLARITY Extension received the last dose of 
CT at the start of year 2 in CLARITY, approxi-
mately 4.5–5.5 years before the end of CLARITY 
Extension. These circumstances may explain 
some of the 11.6% of patients who had a mean 
number of T1 Gd+ lesions ⩾ 1.0 in the CP 
3.5 mg/kg group.
The patterns of observed low-level MRI activity 
did not translate into a detectable clinical activity 
within the study period. The safety and efficacy 
outcomes from CLARITY Extension have been 
described in a separate publication.4 The efficacy 
outcomes showed that there were no significant 
differences in the annualized relapse rates or 
EDSS scores of patients who received CT in 
CLARITY and placebo in CLARITY Extension 
compared with patients who received CT in both 
phases of the study.4 Given the previous observa-
tions of a relationship between MRI activity and 
disease progression, it is possible that the minor 
differences observed in MRI activity during 
CLARITY Extension may ultimately translate 
into clinical differences over much longer time-
scales (i.e. spanning decades). Further studies to 
provide insights into the long-term efficacy of 
treatment with CT are needed, including assess-
ment of the effects of disease activity detectable 
by MRI measurements. Such studies will help to 
determine whether some patients may benefit 
from new treatment with CT after a prolonged 
period without active treatment, such as 4–5 
years.
A limitation of the study is that the baseline char-
acteristics of patients at the start of CLARITY 
Extension may not match the characteristics of 
patients in the original CLARITY study. This 
may have resulted in some selection bias during 
CLARITY Extension. In addition, the variable 
treatment gap was not preplanned and must be 
considered when interpreting the findings of this 
study. The design of CLARITY Extension was 
not finalized until after the CLARITY study had 
Therapeutic Advances in Neurological Disorders 00(0)
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started. Delays also occurred as a result of admin-
istrative issues related to obtaining the necessary 
approvals from the study centres. Although not 
prespecified, the gap does substantially increase 
the overall length of follow up, thus providing 
insights into the long-term effects of treatment 
with CT on safety and efficacy. Other limitations 
that affect these results include inequalities in the 
distribution of patient numbers in the treatment 
arms, which is expected because patients receiv-
ing CT in CLARITY were rerandomized to CT 
3.5 mg/kg or placebo in a 2:1 ratio in CLARITY 
Extension.
In summary, the findings from CLARITY 
Extension suggest that treatment with CT 3.5 
mg/kg has a durable effect on MRI outcomes. 
The mean numbers of T1 Gd+ lesions remained 
well below CLARITY baseline across all treat-
ment groups, including the CP groups, which had 
a higher mean number of T1 Gd+ lesions than 
the CC groups. Furthermore, the majority of 
patients in each treatment group remained free 
from T1 Gd+ lesions, even without retreatment 
after 2 years.
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